Go to Page # Page of 21

The Role of Panitumumab on Redox Status of Colon Cancer Cell Lines

 E. Giannopoulou, K Floratou and H.P. Kalofonos
Description: The FDA granted approval to panitumumab for the treatment of patients with EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, & irrinotecan- containing chemotherapy regimens. Panitumumab is a human IgG2 monoclonal antibody that binds to EGFR and inhibits its phosphorylation & therefore its signaling pathway activation. Colorectal cancer is the 4th most prevalent carcinoma in Western society and the 2nd cause of cancer death.
Views: 2248
Domain: Medical
Category: Biotech/Pharma
The possible role of panitumumab on redox status of colon cancer cell lines DLD-1 and HT-29
E. Giannopoulou, K Floratou and H.P. Kalofonos

Clinical Oncology Laboratory, Division of Oncology, Department of Medicine, University of Patras, Patras, Rio, 26504

�On September 27, 2006, the FDA granted approval to
panitumumab (VectibixTM, Amgen, Inc., Thousand Oaks, CA) for the treatment of ... See more

Recent Presentations

Impact of Clinician Burnout on Patient Safety

Main objective is to identify strategies for improving well-being & resilience in the healthcare workforce. Explain, clinician burnout is a patient care & healthcare workforce prob

Paul Abramowitz
27 June, 2019

Innovation in Allergy Immunotherapy

ASIT biotech treatments consist of a mixture of purified peptides from different selected sizes, produced from natural sources of allergens for allergy immunotherapy.

26 June, 2019
Bionure Farma
25 June, 2019